Your new experience awaits. Try the new design now and help us make it even better

ORIGINAL RESEARCH article

Front. Pharmacol.

Sec. Cardiovascular and Smooth Muscle Pharmacology

Volume 16 - 2025 | doi: 10.3389/fphar.2025.1641422

This article is part of the Research TopicNew Frontiers in Heart Failure Therapy: Mechanisms, Efficacy, and ChallengesView all 8 articles

Exploring the biological basis for the identification of different syndromes in ischemic heart failure based on joint multi-omics analysis

Provisionally accepted
Yilin  ZhangYilin ZhangJingjing  WeiJingjing WeiLijie  QiaoLijie QiaoRui  YuRui YuHongjie  RenHongjie RenAnshe  ZhaoAnshe ZhaoYang  SunYang SunAolong  WangAolong WangBin  LiBin LiXinlu  WangXinlu WangMingjun  ZhuMingjun Zhu*
  • First Affiliated Hospital of Henan University of Traditional Chinese Medicine, Zhengzhou, China

The final, formatted version of the article will be published soon.

Background IHF is a major chronic disease that seriously threatens human health. Qi deficiency and blood stasis syndrome (QDBS), Yang deficiency with blood stasis syndrome (YDBS) and Yang deficiency and blood stasis with fluid retention syndrome (YDBSFR) are the basic syndromes of IHF in Chinese medicine. This study aims to explore the biological basis of the three IHF syndromes through integrated multi-omics research.Methods We analyzed and integrated transcriptomic, proteomic, and targeted metabolomic data from IHF patients and healthy persons to obtain the key biomarkers and enriched pathways of QDBS, YDBS and YDBSFR(Registration No.: ChiCTR2200058314). These biomarkers were combined with clinical indicators to construct the "Disease-Syndromes-Clinical phenotypes-Biomarkers-Pathways" network, and the obtained differential genes and proteins were externally validated.Results The potential biomarkers for QDBS included SDHD, IL10, ACTG1, VWF, MDH2, COX5A, Valeric acid, Succinic Acid and L-Histidine, which were predominantly enriched in TCA cycle, oxidative phosphorylation, platelet activation, and neutrophil extracellular trap formation pathways, demonstrating associations with energy metabolism, coagulation system, and immune-inflammatory responses.YDBS potential biomarkers included TSHR, PRKG1, ATP1A2, GNAI2, APOA2, PLTP, 3-Hydroxybutyrate, Hexadecanoic acid and Palmitelaidic acid, and the combined pathways were mainly enriched in thyroid hormone synthesis, regulation of lipolysis in adipocytes, cholesterol metabolism and PPAR signaling pathways, correlating with hormonal regulation and lipid metabolism. The potential biomarkers of YDBSFR were CNGB1, KCNMA1, PIK3R2, HSPA8, C3, FH, Oxamic acid, N-Acetyl-L-alanine, 4-Hydroxyhippuric acid, and the combined pathways were mainly enriched in aldosterone-regulated sodium reabsorption, cGMP-PKG signaling pathway, neutrophil extracellular trap formation and TCA cycle signaling pathways, which are related to hormone regulation, signal transduction, immune-inflammatory response and energy metabolism. Platelet activation was involved in the whole process of IHF. External validation demonstrated the above core targets.Conclusion This study investigated the biological basis of QDBS, YDBS and YDBSFR in IHF from a modern biomedical perspective, providing references for the objective research of TCM syndrome differentiation.

Keywords: Ischemic heart failure, multi-omics, Biological basis, Syndrome Differentiation, Traditional Chinese Medicine

Received: 05 Jun 2025; Accepted: 30 Jun 2025.

Copyright: © 2025 Zhang, Wei, Qiao, Yu, Ren, Zhao, Sun, Wang, Li, Wang and Zhu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Mingjun Zhu, First Affiliated Hospital of Henan University of Traditional Chinese Medicine, Zhengzhou, China

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.